血浆置换对依诺肝素抗Xa活性和左乙拉西坦血药浓度的影响
本文报告一例52岁女性在接受治疗性血浆置换(TPE)期间使用依诺肝素和左乙拉西坦的病例。通过治疗药物监测发现,TPE后抗Xa活性降至检测不到(<0.1 IU/mL),显著低于预期值0.14 IU/mL;而左乙拉西坦TPE后浓度与预期值无显著差异,仅清除全身储量的5%。提示TPE显著影响依诺肝素抗Xa活性,但对左乙拉西坦清除影响极小。
要点
- TPE可显著降低依诺肝素抗Xa活性,TPE后监测值低于检测下限。
- TPE对左乙拉西坦清除影响小,TPE后浓度与预期值无显著差异。
- 接受TPE的患者需考虑对依诺肝素进行抗Xa活性监测和剂量调整。
核心结论
- 在抗MDA5抗体相关ILD伴皮肌炎并既往癫痫的患者中,TPE显著改变依诺肝素抗Xa活性,TPE后抗Xa活性检测不到。
- TPE对左乙拉西坦清除影响极小,TPE后浓度与基于患者个体药动学数据计算的预期值无显著差异,仅清除全身储量的5%。
研究设计与样本
- 单例病例报告:52岁女性,因抗MDA5抗体相关间质性肺病伴皮肌炎接受TPE,同时使用左乙拉西坦和预防性依诺肝素。
- 采用治疗药物监测原则,采集TPE前、TPE后抗Xa活性和左乙拉西坦血清浓度,以及下次给药后1和6小时左乙拉西坦浓度和TPE废弃血浆左乙拉西坦浓度。
主要发现
- 基于标准群体药动学数据,无TPE时预期抗Xa活性为0.14 IU/mL;TPE后立即采集的抗Xa活性检测不到(<0.1 IU/mL),提示抗Xa活性显著被清除。
- 实测左乙拉西坦TPE后浓度与基于患者个体药动学数据计算的预期TPE后浓度无显著差异。
- TPE仅清除左乙拉西坦全身储量的5%。
临床怎么用
- 接受TPE的患者使用依诺肝素时,应考虑监测抗Xa活性并评估是否需要补充剂量。
- 接受TPE的患者使用左乙拉西坦时,TPE对清除影响小,可能无需常规补充剂量,但仍需个体化评估。
局限性
- 单例病例报告,结果不能推广至所有接受TPE的患者。
- 缺乏TPE对依诺肝素和左乙拉西坦影响的对照数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The effect of therapeutic plasma exchange (TPE) on antifactor Xa activity in a patient treated with enoxaparin and levetiracetam is reported. SUMMARY: A 52-year-old woman was treated with levetiracetam and prophylactic enoxaparin while receiving TPE to manage respiratory failure due to anti-MDA5 antibody-associated interstitial lung disease (ILD) with dermatomyositis. Due to a scant amount of evidence regarding the management of these medications in TPE, therapeutic monitoring principles were used to assess the effect TPE had on these medications. A pre-TPE antifactor Xa activity level and levetiracetam serum assay, a post-TPE antifactor Xa activity level and levetiracetam serum assay, levetiracetam serum assays at 1 and 6 hours after the patient received her next dose, and a levetiracetam assay of the waste plasma from the TPE were collected for therapeutic drug monitoring and pharmacokinetic calculations. Utilizing standard population pharmacokinetic data, the expected antifactor Xa activity without TPE was 0.14 IU/mL. This concentration was significantly higher than the undetectable concentration (<0.1 IU/mL) that was drawn immediately after TPE, suggesting significant removal of antifactor Xa activity. The measured levetiracetam level did not significantly differ from the expected post-TPE levetiracetam level that was calculated using patient-specific pharmacokinetic data. CONCLUSION: In a patient receiving TPE to manage anti-MDA5 antibody ILD associated with dermatomyositis and a prior seizure, TPE significantly altered enoxaparin antifactor Xa activity as evidenced by the undetectable antifactor Xa activity level drawn after TPE. Alternatively, TPE had a minimal effect on the clearance of levetiracetam as evidenced by the post-TPE level and fraction elimination of only 5% of total body stores.
引用
- Peters BJ, Hofer M, Daniels CE, et al. Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels. Am J Health Syst Pharm. 2018. PMID: 30463865. doi:10.2146/ajhp170885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。